Cystic fibrosis is a rare, life-shortening disease that affects over 90,000 people worldwide. It is caused by mutations in the CFTR ion channel, resulting in the aberrant flow of salt and water in ...

The approval of Trikafta will make “a novel treatment available to most cystic fibrosis patients, including adolescents, who previously had no options,” said acting FDA Commissioner Ned Sharpless.

As someone who does not benefit from any CFTR modulators, I only have one option for improving my lung function — transplant. But just because it’s my only choice does not mean it’s an easy one to ...

South Africans living with cystic ... fibrosis drugs, including Kalydeco, Orkambi, Symdeko, and Trikafta. These medications are vital for managing the disease and improving patients' quality of life.

Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...

Cystic fibrosis is a genetic disorder that changes a vital protein in the body, causing a buildup of thick and sticky mucus, ...

Please provide your email address to receive an email when new articles are posted on . Percent-predicted FEV 1, sweat chloride and safety were analyzed in two phase 3 trials of vanzacaftor ...

Vertex Pharmaceuticals said Friday the U.S. Food and Drug Administration expanded its approval of a cystic fibrosis treatment, encompassing more patients with different types of mutations of the ...